Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

02.02.15	Moody's: Pharmaceutical pipelines improve, but patent expiration exposure also edges higher (Moodys)
30.01.15	MARKT USA/Gewinnmitnahmen an Wall Street erwartet - BIP im Blick (Dow Jones)
30.01.15	Biogen Idec Shares Surge 7% As Q4 Adj Profit Tops View, Rosy Outlook (RTTNews)
29.01.15	Biogen Profit Crushes Estimates, FY15 EPS Guidance Strong; Stock Up 7% (RTTNews)
29.01.15	Biogen Idec 2014 Revenues Increase 40% to $9.7 Billion (Businesswire)
29.01.15	Biogen Idec Teams Up To Develop Gene Therapies For Hemophilia (RTTNews)
29.01.15	Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Announce Global Collaboration to Develop Gene Therapies for Hemophilia (Businesswire)
12.01.15	Biogen Idec To Acquire Convergence Pharma - Quick Facts (RTTNews)
12.01.15	Biogen Idec to Expand Neuropathic Pain Portfolio with the Acquisition of Convergence Pharmaceuticals (Businesswire)
09.01.15	Biogen Idec and Columbia University Medical Center to Conduct Collaborative Genetics Research (Businesswire)
08.01.15	Biogen Idec Reports Positive Top-Line Results From Phase 2 Anti-LINGO-1 Trial (RTTNews)
08.01.15	Biogen Idec Reports Positive Top-Line Results from Phase 2 Anti-LINGO-1 Trial in People with Acute Optic Neuritis (Businesswire)
26.11.14	Why Tecfidera Drug Label Is Updated... (RTTNews)
31.10.14	Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA™ (rFVIIIFc) Marketing Authorization Application for Review (Businesswire)
22.10.14	Biogen Idec Earnings Surge Above Estimates, Lifts 2014 Outlook (RTTNews)
22.10.14	Biogen erhöht erneut Prognose nach überraschend gutem Quartal (AWP)
22.10.14	Biogen erhöht erneut Prognose nach überraschend gutem Quartal (dpa-afx)
22.10.14	Biogen Idec Q3 Results Top Estimates; Lifts Full-year EPS View - Quick Facts (RTTNews)
22.10.14	Earnings Watch For October 22 (BA, BSX, XRX, CA, ABT, T) (RTTNews)
12.09.14	Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process) (Businesswire)
11.09.14	Biogen Idec's Phase 3 Study With Tecfidera Show Positive Data Over 5 Years (RTTNews)
11.09.14	Biogen Idec: PLEGRIDY Maintains Positive Treatment Effects In Phase 3 Trial (RTTNews)
11.09.14	New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients (Businesswire)
11.09.14	PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients (Businesswire)
03.09.14	Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care (Businesswire)
26.08.14	Biogen Idec: Health Canada Approves ELOCTATE - Quick Facts (RTTNews)
26.08.14	Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub (Businesswire)
21.08.14	Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions (Businesswire)
16.08.14	Biogen Idec: FDA Approves Plegridy To Treat Multiple Sclerosis (RTTNews)
23.07.14	MÄRKTE USA/Boeing bremst Dow Jones und Apple befeuert Nasdaq (Dow Jones)
23.07.14	PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis (Businesswire)
23.07.14	PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis (Businesswire)
23.07.14	Biotech-Unternehmen Biogen Idec schraubt Prognose erneut nach oben (dpa-afx)
23.07.14	Biotech-Unternehmen Biogen Idec schraubt Prognose erneut nach oben (AWP)
16.06.14	Biogen Idec, AbbVie Announce Positive Results From Phase 3 DECIDE Clinical Trial (RTTNews)
07.06.14	Biogen Idec: FDA Okays Eloctate To Treat Hemophilia A (RTTNews)
30.05.14	Data from Biogen Idec’s Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses (Businesswire)
28.05.14	Array BioPharma Inks Drug Discovery Collaboration Deal With Biogen Idec (RTTNews)
28.05.14	Biogen Idec Announces Official Partnership with Sailing Sclerosis’ "Oceans of Hope” to Globally Change Perceptions of MS (Businesswire)
23.05.14	Biogen Idec Receives Positive CHMP Opinion For Plegridy As Treatment For MS (RTTNews)
23.05.14	CHMP Adopts Positive Opinion for PLEGRIDY™ (Peginterferon Beta-1a) as a Treatment for Multiple Sclerosis in the European Union (Businesswire)
12.05.14	Richard A. Rudick Joins Biogen Idec as Vice President, Development Sciences, Value-Based Medicine (Businesswire)
12.05.14	Biogen Idec and Sobi to Donate 1 Billion International Units of Clotting Factor to Support Treatment of Hemophilia in Developing World (Businesswire)
01.05.14	New TYSABRI® Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients (Businesswire)
30.04.14	Biogen Idec Says New Data Reinforce Efficacy Of TECFIDERA In Patients With RRMS (RTTNews)
30.04.14	New Data Reinforce Efficacy of TECFIDERA® (Dimethyl Fumarate) in MS Patients with High Disease Activity (Businesswire)
29.04.14	Biogen Idec to Present New Two-Year Data from the PLEGRIDY™ (Peginterferon Beta-1a) Phase 3 ADVANCE Study at AAN Annual Meeting (Businesswire)
23.04.14	Biogen Idec Q1 Profit Up 12%, But Misses Estimates; Lifts FY14 View (RTTNews)
23.04.14	Biotech-Unternehmen Biogen Idec hebt nach Gewinnanstieg Prognose an (dpa-afx)
23.04.14	Biotech-Unternehmen Biogen Idec hebt nach Gewinnanstieg Prognose an (AWP)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Verluste in Europa: Euro STOXX 50 letztendlich leichter
20.12.24		NASDAQ-Handel NASDAQ 100 schwächelt zum Start des Freitagshandels
20.12.24		Dow Jones aktuell: Dow Jones fällt zum Start des Freitagshandels zurück
20.12.24		Zurückhaltung in Europa: Euro STOXX 50 präsentiert sich schwächer
20.12.24		Börse Frankfurt: DAX präsentiert sich nachmittags leichter
20.12.24		Börse Frankfurt: So steht der LUS-DAX am Nachmittag
20.12.24		XETRA-Handel TecDAX sackt am Freitagmittag ab

20.12.24

Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones

20.12.24

Verluste in Europa: Euro STOXX 50 letztendlich leichter

20.12.24

NASDAQ-Handel NASDAQ 100 schwächelt zum Start des Freitagshandels

20.12.24

Dow Jones aktuell: Dow Jones fällt zum Start des Freitagshandels zurück

20.12.24

Zurückhaltung in Europa: Euro STOXX 50 präsentiert sich schwächer

20.12.24

Börse Frankfurt: DAX präsentiert sich nachmittags leichter